)
)
)
Grit Biotechnology Inc.
GRIT-BIO is a clinical stage global biotech backed by leading healthcare investors, pioneering advanced immunotherapies for unmet clinical needs in cancers and autoimmune diseases, and completed the filing for the HK stock exchange listing. The main management team of GRIT-BIO (CEO/CEO/CSO) will attend this JPM. Worth noting is Vivacta-BIO is a company spun out from Qiming Venture, dedicated to advancing in vivo CAR-T therapies.
The company has established a robust pipeline of tumour-infiltrating lymphocyte (TIL) cell therapies and off-the-shelf cell therapies. Besides the pipeline products. Our conference focus is to find global partners for our late stage assets (TIL portfolios) and also our assets at early stage (neoantigen cancer vaccine and in vivo CAR). We are expected to initiate IITs and following IND-enabling process for in vivo CAR and neoantigen cancer vaccine very soon. Happy to discuss if there's any kind of collaboration.
** Sorry we don't accept meetings from vendors*
)
){kind=logo}
)
){kind=logo}
){kind=logo}
)
)
)
)